2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task …
JL Zamorano, P Lancellotti… - European heart …, 2016 - academic.oup.com
The task of develo** CPG documents covers not only integration of the most recent
research, but also the creation of educational tools and implementation programmes for the …
research, but also the creation of educational tools and implementation programmes for the …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
Definition, classification and diagnosis of pulmonary hypertension
G Kovacs, S Bartolome, CP Denton… - European …, 2024 - publications.ersnet.org
Pulmonary hypertension (PH) is a haemodynamic condition characterised by elevation of
mean pulmonary arterial pressure (mPAP)> 20 mmHg, assessed by right heart …
mean pulmonary arterial pressure (mPAP)> 20 mmHg, assessed by right heart …
Treatment algorithm for pulmonary arterial hypertension
Pulmonary arterial hypertension leads to significant impairment in haemodynamics, right
heart function, exercise capacity, quality of life and survival. Current therapies have …
heart function, exercise capacity, quality of life and survival. Current therapies have …
The latest in animal models of pulmonary hypertension and right ventricular failure
Pulmonary hypertension (PH) describes heterogeneous population of patients with a mean
pulmonary arterial pressure> 20 mm Hg. Rarely, PH presents as a primary disorder but is …
pulmonary arterial pressure> 20 mm Hg. Rarely, PH presents as a primary disorder but is …
Guidelines for the treatment of pulmonary hypertension (JCS 2017/JPCPHS 2017)
K Fukuda, H Date, S Doi, Y Fukumoto… - Circulation …, 2019 - jstage.jst.go.jp
Pulmonary hypertension remained an unexplained intractable disease with poor prognosis.
In the last 2 decades, however, the diagnosis and treatment methods for this disease …
In the last 2 decades, however, the diagnosis and treatment methods for this disease …
The cancer theory of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) remains a mysterious killer that, like cancer, is
characterized by tremendous complexity. PAH development occurs under sustained and …
characterized by tremendous complexity. PAH development occurs under sustained and …
Potassium channel subfamily K member 3 (KCNK3) contributes to the development of pulmonary arterial hypertension
F Antigny, A Hautefort, J Meloche, M Belacel-Ouari… - Circulation, 2016 - Am Heart Assoc
Background—Mutations in the KCNK3 gene have been identified in some patients suffering
from heritable pulmonary arterial hypertension (PAH). KCNK3 encodes an outward rectifier …
from heritable pulmonary arterial hypertension (PAH). KCNK3 encodes an outward rectifier …
Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study
Background Bi-allelic mutations of the EIF2AK4 gene cause heritable pulmonary veno-
occlusive disease and/or pulmonary capillary haemangiomatosis (PVOD/PCH). We aimed to …
occlusive disease and/or pulmonary capillary haemangiomatosis (PVOD/PCH). We aimed to …